Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

PVP Biologics Scores Support from Takeda for Celiac Disease Treatment

XTALKS VITALS NEWS

Wheat

Celiac disease affects one percent of the world’s population, according to estimates made by the Celiac Disease Foundation.

Share this!

January 9, 2017 | by Sarah Hand, M.Sc.

Takeda Pharmaceuticals and PvP Biologics have entered into a global agreement to co-develop an enzyme – called KumaMax – designed to help treat patients with celiac disease. The enzyme, which was developed by the biotech startup, helps break down gluten in the stomach to prevent the allergen from triggering an immune reaction and causing damage to the small intestine.

“Takeda’s GI experience and capabilities are a great fit with our goal of developing a novel oral enzyme therapy to make a meaningful impact on the lives of people with celiac disease,” said Adam Simpson, president and CEO of PvP Biologics. “In addition, the significant non-dilutive financing provided by Takeda will accelerate therapeutic development of KumaMax.”

PvP Biologics has agreed to conduct all required research and development through Phase I clinical trials. Takeda will provide $35 million in financing, with the option to acquire the biotech after reviewing the data.

“This agreement with PvP Biologics reinforces Takeda’s commitment to developing therapeutics targeting celiac disease. KumaMax could address a significant unmet need for celiac patients who try, but are unable to completely avoid gluten exposure in their diets, and thus continue to experience debilitating symptoms,” said Asit Parikh, head of the gastroenterology therapeutic area for Takeda. “We are pleased to be partnering with PvP Biologics, a company whose management team has a proven track record of successfully bringing assets that target chronic inflammatory gastrointestinal diseases through development.”



KumaMax is a recombinant enzyme which is currently in preclinical development. Enzymatically active at the low pH found in the stomach, KumaMax specifically targets the parts of the gluten protein that stimulate an autoimmune response. There is no treatment for celiac patients, aside from completely avoiding the allergen by adhering to a limiting gluten-free diet.

“Celiac disease is a disorder in which the ingestion of even a trace amount of gluten can damage the small intestine,” said Dr. Tadataka "Tachi" Yamada, chairman of PvP Biologics. “In pre-clinical experiments, KumaMax has shown the ability to degrade gluten with sufficient efficiency and effectiveness to indicate its exciting potential as an oral therapy for a disease that impairs the lives of millions.”

KumaMax could provide a fail-safe for celiac patients who inadvertently ingest gluten, by degrading the allergen before it can enter the small intestine. This could reduce the painful symptoms and intestinal damage associated with accidental gluten consumption.

Celiac disease affects one percent of the world’s population, according to estimates made by the Celiac Disease Foundation. Celiac disease can progress with exposure to gluten, causing gastrointestinal discomfort, malnutrition and weakness.


Keywords: Celiac Disease, Gluten, Biotech


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.